Patients treated with 3 months of CAPOX have a lower recurrence rate compared to those treated with 6 months of FOLFOX, but with poorer tolerance. High-risk stage II colon cancer patients may benefit from shorter chemotherapy duration. Molecular MSI phenotype is associated with a good prognosis in stage II colon cancer. Determining MSI status can help guide adjuvant chemotherapy decisions for high-risk stage II colon cancer patients.